The use of cytokines, fusion proteins and antibodies to treat cutaneous T-cell lymphoma

Dermatologic Therapy

Volumn 16, Issue 4, 2003, Pages 331-336

  Rook, Alain H ^a   McGinnis, Karen S ^a   Richardson, Stephen K ^a   Budgin, Jeanne B ^a   Wysocka, Maria ^a   Benoit, Bernice M ^a   Hopkins, Jacqueline M J ^a   Vittorio, Carmela C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cutaneous T cell lymphoma; Cytokine; Interferon; Interleukin

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CYTOKINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; ETRETINATE; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 12; INTERLEUKIN 2; ISOTRETINOIN; PEGINTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 12; RETINOID;

CANCER STAGING; CAPILLARY LEAK SYNDROME; CELL SURVIVAL; CHILL; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DIARRHEA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOALBUMINEMIA; IMMUNE RESPONSE; KIDNEY FAILURE; MOLECULAR EVOLUTION; MYALGIA; NAUSEA; NEUTROPENIA; REVIEW; SKIN DEFECT; THROMBOCYTOPENIA; TUMOR CELL; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CYTOKINES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKINS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0347360373     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2003.01645.x     Document Type: Review

References (37)

1. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The immunopathogenesis of cutaneous T-cell lymphoma: abnormal cytokine production by Sezary T cells. Arch Dermatol, 1993: 129: 486-489.
2. Wysocka M, Zaki MH, French LE, et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood, 2002: 100: 3287-3294.
3. Vowels BR, Cassin M, Vonderheid E, et al. Aberrant cytokine production by Sézary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992: 99: 90-94.
4. Asadullah K, Docke WD, Haeussler A, Sterry W, Volk HD. Progression of mycosis fimgoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996: 107: 833-837.
5. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995: 32: 448-453.
6. Vermeer MH, van Doorn R, Dukers D, Bekkenk MW, Meijer CJ, Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol, 2001: 19: 4322-4329.
7. Asadullah K, Friedrich M, Docke WD, Jahn S, Vokl HD, Sterry W. Enhanced expression of T-cell activation and natural killer cell antigens indicates systemic anti-tumor response in early cutaneous T-cell lymphoma. J Invest Dermatol 1997: 108: 743-747.
8. Berger CL, Wang N, Christensen I, Longley J, Heald P, Edelson RL. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol, 1996: 107: 392-397.
9. Rook AH, Wood GS, Yoo EK, et al. Interleukin-12 Therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999: 94: 902-908.
10. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Clin North Am, 1995: 9: 1089-1107.
11. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alpha 2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989: 20: 395-407.
12. Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002: 138: 1054-1060.
13. Knobler RM, Radaszkiewicz T. Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa 2b and retinoids. J Am Acad Dermatol 1991: 24: 247-252.
14. Dreno B, Celorier P, Litroux P. Roferon-A in combination with Tegason in cutaneous T-cell lymphomas. Acta Haematol, 1993: 89 (Suppl. 1): 28-32.
15. Kuzel TM, Gilyon K, Springer E, et al. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst, 1990: 82: 203-207.
16. Gottlieb SL, Wolfe JT, Fox FE, et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and with recombinant interferon alfa. J Am Acad Dermatol, 1996: 35: 946-957.
17. Shapiro M, Rook AH, Lehrer MS, Junkins Hopkins JM, French LE, Vittorio CC. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. J Am Acad Dermatol, 2002: 47: 956-961.
18. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol, 2002: 47: 672-684.
19. Kaplan EH, Rosen ST, Norris DB, et al. Phase II study of recombinant human interferony for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst, 1990: 82: 208-212.
20. Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Sezary syndrome regulation by interferon alfa and interleukin 12. J Am Acad Dermatol 2001: 44: 28-32.
21. Platsoucas CD, Fox FE, Oleszak E, et al. Regulation of natural killer cytotoxicity by recombinant alpha interferons: augmentation by IFN-alpha 7, an interferon similar to IFN-alpha. J Anticancer Res 1989: 9: 849-858.
22. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 2001: 15: 419-429.
23. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology, 2001 August: 34: 395-403.
24. Rook AH, Kubin M, Cassin M, et al. Interleukin 12 reverses cytokine and immune abnormalities in Sézary syndrome. J Immunol 1995: 154: 1491-1498.
25. Fox FE, Niu Z, Lessin S, et al. Cytokine regulation of the growth of clonal malignant T-cells from patients with Sézary syndrome. [Abstract.] J Invest Dermatol, 1997: 108: 552.
26. Marolleau JP, Baccard M, Flageul B, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol, 1995: 131: 574-579.
27. Zaki MH, Wysocka M, Everetts SE, et al. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T-cell lymphoma. J Invest Dermatol 2002: 118: 366-371.
28. Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer 1997: 33 (Suppl.): S34-S36.
29. 389 IL-2 (ONTAK) for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001: 19: 376-388.
30. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 2002: 100: 1399-1403.
31. Waldmann TA, White JK, Goldman CD, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1993: 82: 1701-1712.
32. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990: 35: 118-127.
33. Buggins AGS, Mufti GJ, Salisbury J et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002: 100: 1715-1720.
34. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol, 2002: 19 (Suppl.): S27-S32.
35. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90 labeled anti-Tac. Blood, 1995: 86: 4063-4075.
36. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol, 2000: 18: 1622-1636.
37. Foss FM, Raubitscheck A, Mulshine JL, et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5 expressing leukemia and lymphoma. Clin Cancer Res, 1998: 4: 2691-2700.